Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 1
1944 1
1945 5
1946 4
1948 1
1949 1
1951 1
1952 1
1954 1
1955 1
1968 1
1973 1
1975 1
1978 1
1979 1
1980 2
1981 2
1982 4
1983 2
1985 1
1987 2
1988 2
1989 6
1990 5
1991 2
1992 3
1993 3
1994 2
1995 2
1996 4
1997 1
1998 4
1999 4
2000 4
2001 7
2002 9
2003 10
2004 10
2005 15
2006 9
2007 8
2008 12
2009 19
2010 21
2011 35
2012 47
2013 42
2014 57
2015 24
2016 39
2017 55
2018 74
2019 94
2020 90
2021 102
2022 102
2023 110
2024 54

Text availability

Article attribute

Article type

Publication date

Search Results

1,063 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Among authors: shah ma. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Sun JM, et al. Among authors: shah ma. Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. Lancet. 2021. PMID: 34454674 Clinical Trial.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Shah MA, et al. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. Nat Med. 2023. PMID: 37524953 Free PMC article. Clinical Trial.
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Kojima T, et al. Among authors: shah ma. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. J Clin Oncol. 2020. PMID: 33026938 Clinical Trial.
Improving outcomes in patients with oesophageal cancer.
Shah MA, Altorki N, Patel P, Harrison S, Bass A, Abrams JA. Shah MA, et al. Nat Rev Clin Oncol. 2023 Jun;20(6):390-407. doi: 10.1038/s41571-023-00757-y. Epub 2023 Apr 21. Nat Rev Clin Oncol. 2023. PMID: 37085570 Review.
Dietary fructose improves intestinal cell survival and nutrient absorption.
Taylor SR, Ramsamooj S, Liang RJ, Katti A, Pozovskiy R, Vasan N, Hwang SK, Nahiyaan N, Francoeur NJ, Schatoff EM, Johnson JL, Shah MA, Dannenberg AJ, Sebra RP, Dow LE, Cantley LC, Rhee KY, Goncalves MD. Taylor SR, et al. Among authors: shah ma. Nature. 2021 Sep;597(7875):263-267. doi: 10.1038/s41586-021-03827-2. Epub 2021 Aug 18. Nature. 2021. PMID: 34408323 Free PMC article.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. Shah MA, et al. J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5. J Clin Oncol. 2023. PMID: 36603169
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.
Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG; JRI Live Cell Bank; Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF. Goc J, et al. Among authors: shah ma. Cell. 2021 Sep 16;184(19):5015-5030.e16. doi: 10.1016/j.cell.2021.07.029. Epub 2021 Aug 17. Cell. 2021. PMID: 34407392 Free PMC article.
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.
D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. D'Alise AM, et al. Among authors: shah ma. Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604. Epub 2022 Aug 10. Sci Transl Med. 2022. PMID: 35947675 Free PMC article.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. Klempner SJ, et al. Among authors: shah ma. Clin Cancer Res. 2023 Oct 2;29(19):3882-3891. doi: 10.1158/1078-0432.CCR-23-0204. Clin Cancer Res. 2023. PMID: 37490286 Free PMC article. Clinical Trial.
1,063 results